NCT04125745View on ClinicalTrials.gov

Oral CXA-10 in Pulmonary Arterial Hypertension

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

October 31, 2019

Primary Completion Date

December 1, 2020

Study Completion Date

December 1, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

CXA-10

Each subject will receive oral CXA-10 at the dose of 300 mg once daily for 12 weeks

Trial Locations (1)

15213

University of Pittsburgh, Pittsburgh

Sponsors

Collaborators (1)

Complexa, Inc.
All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Complexa, Inc.

INDUSTRY

lead

Gladwin, Mark, MD

INDIV